Business
Reporting Q4 and full year earnings on Wednesday, J&J executives hailed growth across the healthcare giant’s portfolio while standing fast on its talc lawsuit and tariffs.
FEATURED STORIES
Henry Gosebruch, who has $3.5 billion in capital to deploy, is thinking broad as he steers the decades-old biotech out of years of turmoil.
Speaking on the sidelines of the J.P. Morgan Healthcare Conference, Novo business development executive Tamara Darsow said the company is gunning for obesity and diabetes assets.
It doesn’t matter how many times you have traversed Union Square; no one knows which way is north, or where The Westin is in relation to the Ritz Carlton. A Verizon outage brought that into focus on Wednesday.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Stoughton, Mass.-based Collegium Pharmaceutical is expanding its pain-treating portfolio with a $604 million buyout of Raleigh’s BioDelivery Sciences International (BDSI).
Moderna is reportedly in talks with the UK government to establish mRNA manufacturing facilities in the country, as well as collaborating with health authorities on clinical trials.
Exo Therapeutics’ approach is not only different, it has revolutionary potential.
The fund will be used to target partnerships with promising early-stage biotechnology to enhance Fujifilm’s life sciences portfolio.
Curevo, a clinical-stage biotechnology company, is developing safe and highly-effective vaccines to fight infectious diseases such as shingles.
Well into the new year, biopharma and life sciences companies bolster their executive leadership teams and boards with these Movers & Shakers.
The London-based Financial Times reported that 83% of companies listed on stock exchanges over the past two years are now trading well below their initial public offering price.
Shares of Alnylam Pharmaceuticals are sliding in morning trading despite the news that the company’s revenues grew by 83% in 2021 compared to the previous year.
Bayer joined in the $50 million Series A for San Francisco’s Indapta Therapeutics.
As AstraZeneca released its 2021 annual financial report, a BBC documentary suggested that the way scientists and politicians politicized its COVID-19 vaccine may have cost lives.